Hemostemix opens enrollment for VesCell vascular dementia trial under Bahamas LARTA

• Hemostemix moved to commercialize an investigational VesCell clinical trial for vascular cognitive impairment under the Bahamas’ LARTA framework.
• Enrollment is underway, with the program designed to assess safety, feasibility, and early signs of cognitive and functional benefit.
• No trial results were presented; a future investor and medical webinar was scheduled for 12:00 EST to outline the proposed study.
• The company positioned VesCell as a potential option in an area with no FDA-approved therapy targeting vascular cognitive impairment.
• VesCell remains unapproved in the US or Canada for vascular cognitive impairment or vascular dementia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemostemix Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608200944NEWSFILECNPR____20260820_310607_1) on August 20, 2026, and is solely responsible for the information contained therein.